Netarsudil Mesylate

Netarsudil Mesylate is a Rho kinase inhibitor with norepinephrine transport inhibitory activity. It is FDA-approved for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or hypertensive eye disease.

Netarsudil ophthalmic solution: Conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage, instillation site erythema, corneal staining, blurred vision, increased lacrimation, eyelid erythema, reduced visual acuity.
Netarsudil and latanoprost ophthalmic solution: Conjunctival hyperemia, instillation site pain, corneal verticillata, conjunctival hemorrhage, ocular itching, decreased visual acuity, increased lacrimation, instillation site discomfort, blurred vision.